secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001193125-23-088185
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics adopts one-year stockholder rights plan to support strategic review
--------------------------------------------------------------------------------

- Rights plan triggers at 10% beneficial ownership; each right entitles holder to purchase preferred stock units at $3.75.
- Plan expires March 30, 2024; includes qualifying offer clause allowing 10% of stockholders to call special meeting.
- Board previously announced comprehensive strategic review to maximize shareholder value; rights plan provides time for review.
- No dead-hand, slow-hand, or similar features; Board can redeem rights for $0.001 per right until trigger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523088185/0001193125-23-088185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523088185/d436260d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-088185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer